TAIPEI, Taiwan, Feb. 17, 2018 -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of medical need in pain management, ophthalmology, and oncology, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering in the United States of its American Depositary Shares (ADSs) representing shares of common stock. All ADSs to be sold in the offering will be offered by TLC. The number of ADSs to be offered and the price for the proposed offering have not yet been determined. TLC has applied to list its ADSs on The Nasdaq Global Market under the trading symbol "TLC".
Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. CLSA Limited, H.C. Wainwright & Co., LLC, Janney Montgomery Scott LLC, and Laidlaw & Company (UK) Ltd. are acting as co-managers.
The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor New York, New York 10022; Email: [email protected].
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contact:
Dawn Chi
Corporate Communications
Tel: +886 (0)2 2655 7377 ext 136
Email: [email protected]


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



